Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519955 | 0.88 | CHRM2 (0.49) | CHRM2ADRB2ADRB1DRD2TAAR1 | |
| SCHEMBL3173731 | 0.82 | L3MBTL1 (0.48) | ADRB2ADRB1DRD2CNR1TP53 | |
| SCHEMBL13509275 | 0.81 | CHRM2 (0.51) | CHRM2ADRB2ADRB1DRD2TAAR1 | |
| SCHEMBL10834316 | 0.79 | TAAR1 (0.69) | CHRM2TAAR1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10880242 | 0.78 | CHRM2 (0.58) | CHRM2TAAR1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4517657 | 0.77 | ADRB2 (0.48) | CHRM2ADRB2ADRB1DRD2TAAR1 | |
| SCHEMBL7242777 | 0.76 | TAAR1 (0.60) | CHRM2TAAR1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24494846 | 0.74 | CHRM2 (0.58) | CHRM2TAAR1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8989707 | 0.73 | TDP1 (0.56) | — | |
| SCHEMBL4589981 | 0.73 | TAAR1 (0.41) | TAAR1CYP3A4CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2008104790-A1 | SALTS OF A SELECTIVE BETA-2 ANDRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ADRB2, ADRA2A, ADRA2B | CHRM2 134/4885ADRB2 1/4885ADRB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.